AngioDynamics, Inc. ANGO

Despite accelerating revenue growth, Delta stock is struggling to reclaim its 50-day line ahead of its Q3 earnings report.

LATHAM, N.Y., October 02, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York have been selected as an ALPHA-PE Research Fund award recipients. The independent, investigator-led study, supported in partnership with The PERT C

LATHAM, N.Y., September 28, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.

LATHAM, N.Y., July 28, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences:

Moby summary of AngioDynamics, Inc.'s Q4 2026 earnings call

AngioDynamics Inc (ANGO) reports robust revenue increases driven by MedTech and NanoKnife segments, despite facing net losses and competitive market pressures.

AngioDynamics Inc. (NASDAQ:ANGO) delivered stronger-than-expected fourth-quarter results on Tuesday, beating Wall Street forecasts for both revenue and adjusted earnings while issuing an upbeat sales outlook for fiscal 2027.

LATHAM, N.Y. (AP) — AngioDynamics Inc. (ANGO) on Tuesday reported a loss of $11.4 million in its fiscal fourth quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 27 cents. For the year, the company reported that its loss widened to $36.7 million, or 88 cents per share.

LATHAM, N.Y., July 14, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2026, which ended May 31, 2026.